Drugs by condition
Drugs approved for als (amyotrophic lateral sclerosis)
Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
3
Still marketed, NDA or BLA
Drug classes
3
Novel drugs
1
New molecular entities and new biologics
In development
22
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for als (amyotrophic lateral sclerosis).
- Qalsody (Tofersen) · Biogen Ma NovelAccelerated approvalPriority reviewOrphanApr 25, 2023
- Radicava Ors (Edaravone) · Shionogi Priority reviewOrphanMay 12, 2022
- Tiglutik Kit (Riluzole) · Italfarmaco SA OrphanSep 5, 2018
All approved drugs for als (amyotrophic lateral sclerosis), by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 6 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Antisense Oligonucleotide (1)
- Qalsody Tofersen · Biogen Ma · 2023
Benzothiazole (1)
- Tiglutik Kit Riluzole · Italfarmaco SA · 2018
Class not listed in FDA's data (1)
- Radicava Ors Edaravone · Shionogi · 2022
Drugs in development for als (amyotrophic lateral sclerosis)
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- Test drug CB03-154 groupPhase 32 trials
Shanghai Zhimeng Biopharma, Inc. · ALS (Amyotrophic Lateral Sclerosis), Focal Epilepsy
- COYA 302Phase 31 trial
Coya Therapeutics · Amyotrophic Lateral Sclerosis (ALS)
- ION363Phase 31 trial
Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis
- MN-166ibudilastPhase 31 trial
MediciNova · Amyotrophic Lateral Sclerosis
- ALT001Phase 22 trials
Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. · Ischemic Stroke in the Sequelae Stage, Amyotrophic Lateral Sclerosis (ALS)
- CNMAu8gold nanocrystalsPhase 22 trials
Clene Nanomedicine · Amyotrophic Lateral Sclerosis, Multiple Sclerosis
- Foralumab NasalPhase 22 trials
Tiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
- VHB937Phase 22 trials
Novartis · Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease
- AMT-162Phase 21 trial
UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis
- AP-101Phase 21 trial
AL-S Pharma · Amyotrophic Lateral Sclerosis
- BIIB147Phase 21 trial
Biogen · Amyotrophic Lateral Sclerosis
- CORT113176DazucorilantPhase 21 trial
Corcept Therapeutics · Amyotrophic Lateral Sclerosis
- FHND1002Phase 21 trial
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Amyotrophic Lateral Sclerosis (ALS)
- LTX-002Phase 21 trial
Leal Therapeutics, Inc · Amyotrophic Lateral Sclerosis
- NB-4746Phase 21 trial
Nura Bio · Amyotrophic Lateral Sclerosis (ALS)
- NX210cPhase 21 trial
Axoltis Pharma · Amyotrophic Lateral Sclerosis
- PLL001Phase 21 trial
PLL TX AUSTRALIA PTY LTD · Amyotrophic Lateral Sclerosis, ALS
More on als (amyotrophic lateral sclerosis): recruiting trials · published research
Related in neurology: Alzheimer's disease · Parkinson's disease · Multiple sclerosis · Epilepsy and seizures · Migraine · Myasthenia gravis · Spinal muscular atrophy · Duchenne muscular dystrophy · Huntington's disease chorea · Tardive dyskinesia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.